The company, helmed by BioNTech alums, is developing therapies aimed at dermatological, respiratory and gut-related ...

The Chinese company is deploying the technology in its in-house pipeline in AG126, an antibody prodrug targeting the immune checkpoint CTLA4. That's the same target as Bristol-Myers Squibb's ...

NAYA Biosciences has announced the expansion of its bifunctional antibody pipeline to include a novel PD-1 x VEGF tetravalent antibody, NY-500, targeted at hepatocellular carcinoma (HCC ...

ImmunoPrecise Antibodies (IPA) announced the launch of its AI-powered pipeline of both optimized and new therapeutics. By combining advanced artificial intelligence with first-principles thinking ...

complementing the Company’s anti-CD19 antibody, budoprutug. "Adding CLYM116 to our pipeline represents a pivotal moment for Climb Bio as we advance our ambition of becoming a leader in ...

Mr. Seo outlined IND submission timelines of its novel drug pipeline with plans to develop 13 new drugs by 2028, including 9 ADCs and 4 multispecific antibodies. Jin-Seok Seo added, ''Just two ...

By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs.